Curative Efficacy of Tetramethylpyrazine in Combination with Ipratropium Bromide in Treatment of Bronchial Asthma and Its Effects on Inflammatory Factors and Leptin
10.11842/wst.2015.06.018
- VernacularTitle:川芎嗪联合异丙托溴铵治疗支气管哮喘疗效及对患者炎性因子和瘦素的影响
- Author:
Shoubin CHENG
;
Zongxing OU
;
Chunli LIU
- Publication Type:Journal Article
- Keywords:
Tetramethylpyrazine;
ipratropium bromide;
bronchial asthma;
pulmonary function;
inflammatory factor;
leptin
- From:
World Science and Technology-Modernization of Traditional Chinese Medicine
2015;(6):1220-1224
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to investigate the clinical effect of tetramethylpyrazine in combination with ipratropium bromide in the treatment of bronchial asthma and its effects on inflammatory factors and leptin. According to inclusion criteria, a total of 124 bronchial asthma cases were included and randomly divided into two groups, which were the control group (n = 62) and the observation group (n = 62) with the random number table. Besides conventional treatments, the control group was given ipratropium bromide; while the observation group was given tetramethylpyrazine in combination with ipratropium bromide. Then, comparisons were made between two groups on the therapeutic efficacy rate, pulmonary function, inflammatory factor, leptin, and incidence of adverse reactions. The results showed that the total therapeutic efficacy rate was 96.8% in the observation group, which was obviously higher than that of 87.1% in the control group (P < 0.05). In comparison with the control group, the posttreatment pulmonary function indexes PEF and FEV1/FVC increased, inflammatory factors IL-6 and IL-4 decreased, and IL-12 increased in the observation group with statistical significance (P < 0.05). One week, 2 weeks and 4 weeks after the treatment, the level of leptin in the observation group was significantly lower than that in the control group (P < 0.05). During the treatment, there were no severe adverse reactions. The incidence of adverse reactions in the observation group was 11.3%, which was statistically the same with that of 14.5% in the control group (P > 0.05). It was concluded that tetramethylpyrazine in combination with ipratropium bromide was effective for bronchial asthma treatment, which can significantly increase curative efficacy, improve pulmonary function, alleviate inflammatory reaction and reduce leptin level with minor adverse reactions. It required further studies in the clinical practice.
